For years, we’ve been taught to avoid testosterone therapy (TRT) in any man with a history of prostate cancer (PrCa). The fear? That giving testosterone might “feed the fire” and cause cancer recurrence. But recent research is challenging that old belief—and giving us clearer guidance on when TRT can be safe and helpful. 

Let’s break it down.

When TRT May Be Safe After Prostate Cancer

1. After Radical Prostatectomy (RP) with Undetectable PSA
If a patient has had their prostate removed and has undetectable PSA (<0.1 ng/mL) for at least 1–2 years, TRT may be considered.

• Data: No increase in recurrence rates was seen in men on TRT post-RP, even with long-term follow-up (Cardoso et al., 2021; Kacker et al., 2016).
• Guideline: AUA (2018) allows TRT in these cases with informed consent and close monitoring.
   

2. After Radiation Therapy (RT) with Stable PSA
Men who’ve had external beam or brachytherapy and have stable, low PSA values may also be candidates.

• Data: Studies show no increase in recurrence among men on TRT post-RT (Pastuszak et al., 2015; Kaplan et al., 2021).
• Guideline: EAU (2023) cautiously supports TRT in these men, especially with multidisciplinary input.
   

3. During Active Surveillance for Low-Risk PrCa
Though more controversial, some experts consider TRT for men with Gleason ≤6 disease and low PSA.

• Data: No disease progression was noted in small cohorts (Morgentaler et al., 2011; Cil et al., 2020).
• Note: No major guideline currently endorses this; case-by-case decision-making is key.
   

4. Symptomatic Hypogonadism
If a man has clear symptoms of low testosterone and levels <300 ng/dL, TRT can improve energy, mood, libido, and muscle mass.

• Data: TRT improved quality of life without raising recurrence in long-term follow-up (Mulhall et al., 2018).
• Clinical Tip: Always pair with PSA, testosterone monitoring, and regular DRE.
   

When TRT Should Be Avoided

1. Detectable or Rising PSA After Treatment
Men with PSA >0.2 ng/mL post-RP or PSA nadir +2 after RT are at risk for recurrence.

• Guideline: AUA and EAU advise against TRT in these cases.
• Historical Note: The androgen theory of PrCa stems from foundational research by Huggins and Hodges (1941).
   

2. High-Risk or Metastatic Disease
TRT is not for men with Gleason ≥8, PSA >20, or known metastases.

• Evidence: Even bipolar androgen therapy (BAT) is reserved for clinical trials (Schweizer et al., 2016).
• Guideline: EAU (2023) prohibits TRT in advanced disease outside trials.
   

3. Less Than 1–2 Years Post-Treatment
Early TRT (before 1–2 years of undetectable PSA) may pose higher recurrence risk.

• Expert Recommendation: Wait at least 1–2 years post-RP or RT before considering TRT (Kaplan et al., 2021).
   

4. Asymptomatic Hypogonadism or Inadequate Monitoring
Low testosterone without symptoms? Skip TRT.
Can’t commit to regular follow-up? Also a no-go.

• Guideline: AUA (2018) stresses patient selection, monitoring, and shared decision-making.
   

Clinical Perspective: The Saturation Model

According to the saturation model (Morgentaler & Traish, 2009), prostate cells have a threshold for testosterone. Once receptors are saturated, adding more testosterone may not promote growth—especially in low-risk men. It’s a compelling concept, but long-term safety data remain limited.

Key Takeaways for Practice

• Testosterone therapy can be safe for men with low-risk prostate cancer and stable disease—but only with proper selection and monitoring.
• Not every man with a history of prostate cancer is a candidate.
• Use shared decision-making, document informed consent, and engage in team-based care with urologists and oncologists.
• Monitor closely: PSA and testosterone every 3–6 months, plus regular DRE.

Final Thoughts

Testosterone therapy after prostate cancer treatment is no longer a blanket “no.” In well-selected, well-monitored men, it can improve quality of life—without compromising oncologic outcomes. Let’s stay informed and help patients live better lives, safely.

To Learn more Relevant Recent Podcast Episode – Does Testosterone Fuel or Protect Against Prostate Cancer? With Dr. Mohit Khera,   YouTube,  Apple Podcasts / Spotify / Amazon — Episode 154

References

Cardoso MF, Front Oncol, 2021.

Kacker R, Asian J Androl, 2016.

Pastuszak AW, J Urol, 2015.

Kaplan AL, Urol Oncol, 2021.
Morgentaler A, J Urol, 2011; Eur Urol, 2009.

Mulhall JP, J Urol, 2018.

Schweizer MT, J Clin Oncol, 2016.
EAU Guidelines, 2023.
AUA Guidelines, 2018.

Huggins C & Hodges CV, Cancer Res, 1941.